Advertisement
Short survey| Volume 11, ISSUE 2, P191-193, March 2020

How cancer therapeutics cause accelerated aging: Insights from the hallmarks of aging

  • Addie Hill
    Correspondence
    Corresponding author at: Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd. Duarte, CA 91010 United States.
    Affiliations
    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, United States

    Center for Cancer and Aging, City of Hope Comprehensive Cancer Center, Duarte, California, United States
    Search for articles by this author
  • Jaya Sadda
    Affiliations
    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, United States

    Center for Cancer and Aging, City of Hope Comprehensive Cancer Center, Duarte, California, United States
    Search for articles by this author
  • Mark A. LaBarge
    Affiliations
    Department of Population Sciences, City of Hope Comprehensive Cancer Center, United States
    Search for articles by this author
  • Arti Hurria
    Affiliations
    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, United States

    Center for Cancer and Aging, City of Hope Comprehensive Cancer Center, Duarte, California, United States
    Search for articles by this author
Published:March 21, 2019DOI:https://doi.org/10.1016/j.jgo.2019.03.007
      It is not uncommon in clinical practice to see a patient who is receiving cancer treatment appear to age before your eyes. For example, a healthy sixty-five year old female who “appears her stated age” is diagnosed with locally advanced breast cancer and receives doxorubicin, cyclophosphamide, and paclitaxel. By the time she completes chemotherapy she “appears older than her stated age.” The intensity of the treatment seems to correlate with the rapidity of the aging process, with a bone marrow transplant being an optimal example, whereby mantle radiation or chemoablation has been associated with accelerating parameters of physiological aging by as much as 20 years [
      • Arora M.
      • Sun C.L.
      • Ness K.K.
      • et al.
      Physiologic frailty in nonelderly hematopoietic cell transplantation patients: results from the bone marrow transplant survivor study.
      ]. After treatment is withdrawn, the acceleration of aging does seem to slow down, sometimes even reverse, but often does not return to a pre-treatment level. How do we understand the potential biologic underpinnings of this well-known clinical observation? Perhaps merging the field of geriatrics (through understanding the hallmarks of aging) with oncology (through understanding the mechanism of action of common cancer therapies) can provide insights into this phenomenon.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Geriatric Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Arora M.
        • Sun C.L.
        • Ness K.K.
        • et al.
        Physiologic frailty in nonelderly hematopoietic cell transplantation patients: results from the bone marrow transplant survivor study.
        JAMA Oncol. Oct 1 2016; 2: 1277-1286
        • Lopez-Otin C.
        • Blasco M.A.
        • Partridge L.
        • Serrano M.
        • Kroemer G.
        The hallmarks of aging.
        Cell. 2013; 153 (Jun 6): 1194-1217
      1. Highlights of Prescribing Information: Lynparza® (olaparib) tablets.
        in: U.S. Food and Drug Administration. 2019
      2. Highlights of prescribing information: farydak (panobinostat) capsules.
        in: U.S. Food and Drug Administration. 2019
      3. Highlights of prescribing information: Ninlaro (ixazomib) capsules.
        in: U.S. Food and Drug Administration. 2019
        • Barzilai N.
        • Huffman D.M.
        • Muzumdar R.H.
        • Bartke A.
        The critical role of metabolic pathways in aging.
        Diabetes. Jun 2012; 61: 1315-1322
      4. Highlights of prescribing information: Afinitor (everolimus) tablets.
        in: U.S. Food and Drug Administration. 2019
        • Harrison D.E.
        • Strong R.
        • Sharp Z.D.
        • et al.
        Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.
        Nature. Jul 16 2009; 460: 392-395
        • Wilkinson J.E.
        • Burmeister L.
        • Brooks S.V.
        • et al.
        Rapamycin slows aging in mice.
        Aging Cell. Aug 2012; 11: 675-682
        • Doonan R.
        • McElwee J.J.
        • Matthijssens F.
        • et al.
        Against the oxidative damage theory of aging: superoxide dismutases protect against oxidative stress but have little or no effect on life span in Caenorhabditis elegans.
        Genes Dev. Dec 1 2008; 22: 3236-3241
      5. Highlights of prescribing information: Venclexta (venetoclax) tablets.
        in: U.S. Food and Drug Administration. 2019
        • Campisi J.
        Aging, cellular senescence, and cancer.
        Annu Rev Physiol. 2013; 75: 685-705
      6. Highlights of prescribing information: Ibrance (palbociclib) capsules.
        in: U.S. Food and Drug Administration. 2019
      7. Highlights of prescribing information: Keytruda (pembrolizumab) injection.
        in: U.S. Food and Drug Administration. 2019
      8. Highlights of prescribing information: Opdivo (nivolumab) injection.
        in: U.S. Food and Drug Administration. 2019